Show/Hide Menu

Proprietary Product Portfolio

The continued success of its partnered discovery segment provides MorphoSys with the adequate resources to channel substantial investment into proprietary R&D. Its in-house development organization focuses on the development of promising therapeutic antibody candidates in the area of inflammation and oncology. Learn more about the our programs which are in clinical evaluation:

MorphoSys is committed to expanding its proprietary portfolio. We believe that each program has a substantial therapeutic potential.

Dr. Arndt Schottelius
Chief Development Officer

Clinical Programs

MOR208

MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

Further Information

MOR103

MOR103 is a fully human HuCAL antibody directed against GM-CSF (granulocyte macrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases, i.e. rheumatoid arthritis, where current treatment options are inadequate.

Further Information

MOR202

MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma (MM) and certain leukemias. 

Further Information

MOR209/ES414

MOR209/ES414 is an anti-PSMA/anti-CD3 bi-specific antibody based on the ADAPTIRTM (modular protein technology) platform targeting prostate cancer. 

Further Information